文献速递血液净化与透析

美国腹膜透析起始患者转血液透析的预测工具

Transfers to Hemodialysis Among US Patients Initiating Renal Replacement Therapy With Peritoneal Dialysis.
PubMed 文献 · Am J Kidney Dis · 2019-07-10

中位随访21.6个月期间,41.2%转血液透析,25.9%死亡,17.1%接受肾移植;腹膜炎与转血液透析风险升高相关(HR 1.82)。

要点

  • 腹膜透析起始后5年内大部分患者停止该治疗,转血液透析最常见。
  • 腹膜炎发作与转血液透析风险升高独立相关(HR 1.82)。
  • 基于起始临床特征的风险四分位数可分层预测1至4年转血液透析风险。

核心结论

  • 大多数以腹膜透析起始肾脏替代治疗的患者在5年内停止腹膜透析,转血液透析是最常见结局。
  • 患者特征、合并疾病及腹膜炎发作影响转血液透析、死亡和肾移植的概率。
  • 基于起始临床特征的风险四分位数评分可预测转血液透析风险。

研究设计与样本

  • 中位随访21.6个月(四分位距9.0-42.3个月)。

主要发现

  • 随访期间41.2%转血液透析,25.9%死亡,17.1%接受肾移植。
  • 11733例(40.2%)患者有腹膜炎索赔记录。
  • 仍接受腹膜透析的患者比例在22.6个月时降至<50%,5年时降至14.2%。
  • 腹膜炎与转血液透析率升高相关(HR 1.82;95% CI 1.76-1.89;P < 0.001)。
  • 转血液透析风险四分位数评分越高,转血液透析率越高:第2、3、4四分位相比第1的HR分别为1.31(95% CI 1.25-1.37)、1.51(95% CI 1.45-1.58)、1.78(95% CI 1.71-1.86),均P < 0.001。

临床怎么用

  • 可利用基于起始临床特征的风险四分位数评分识别高转血液透析风险患者,加强随访。
  • 腹膜炎发作提示转血液透析风险增加,应重视腹膜炎预防和管理。

局限性

  • 观察性数据,依赖医疗证据报告和医疗保险索赔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Identifying patients who are likely to transfer from peritoneal dialysis (PD) to hemodialysis (HD) before transition could improve their subsequent care. This study developed a prediction tool for transition from PD to HD. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Adults initiating PD between January 2008 and December 2011, followed up through June 2015, for whom data were available in the US Renal Data System (USRDS). PREDICTORS: Clinical characteristics at PD initiation and peritonitis claims. OUTCOMES: Transfer to HD, with the competing outcomes of death and kidney transplantation. ANALYTICAL APPROACH: Outcomes were ascertained from USRDS treatment history files. Subdistribution hazards (competing-risk) models were fit using clinical characteristics at PD initiation. A nomogram was developed to classify patient risk at 1, 2, 3, and 4 years. These data were used to generate quartiles of HD transfer risk; this quartile score was incorporated into a cause-specific hazards model that additionally included a time-dependent variable for peritonitis. RESULTS: 29,573 incident PD patients were followed up for a median of 21.6 (interquartile range, 9.0-42.3) months, during which 41.2% transferred to HD, 25.9% died, 17.1% underwent kidney transplantation, and the rest were followed up to the study end in June 2015. Claims for peritonitis were present in 11,733 (40.2%) patients. The proportion of patients still receiving PD decreased to <50% at 22.6 months and 14.2% at 5 years. Peritonitis was associated with a higher rate of HD transfer (HR, 1.82; 95% CI, 1.76-1.89; P < 0.001), as were higher quartile scores of HD transfer risk (HRs of 1.31 [95% CI, 1.25-1.37), 1.51 [95% CI, 1.45-1.58], and 1.78 [95% CI, 1.71-1.86] for quartiles 2, 3, and 4 compared to quartile 1 [P < 0.001 for all]). LIMITATIONS: Observational data, reliant on the Medical Evidence Report and Medicare claims. CONCLUSIONS: A large majority of the patients who initiated renal replacement therapy with PD discontinued this modality within 5 years. Transfer to HD was the most common outcome. Patient characteristics and comorbid diseases influenced the probability of HD transfer, death, and transplantation, as did episodes of peritonitis.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. McGill RL, Weiner DE, Ruthazer R, et al. Transfers to Hemodialysis Among US Patients Initiating Renal Replacement Therapy With Peritoneal Dialysis. Am J Kidney Dis. 2019. PMID: 31301926. doi:10.1053/j.ajkd.2019.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。